Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma

Completed · Phase 2

Conditions studied: Thymoma, Thymic Carcinoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patients who have advanced thymoma.

Key facts

Study ID

NCT00010257

Run by

Eastern Cooperative Oncology Group

People needed

46

Starts

2001-06-19

Expected to finish

2012-08-01

Last updated by the study team

2023-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery
• Extensive disease (distant disease, pleural disease, pulmonary with or without mediastinal disease, or recurrent progressive disease in site of prior radiotherapy)
• Advanced limited disease allowed if ineligible for primary radiotherapy or surgery
• Measurable disease
• Age 18 and over
• ECOG Performance Status 0-1
• Granulocyte count at least 1,500 cells/mm\^3
• Platelet count at least 100,000 cells/mm\^3
• Bilirubin no greater than 1.5 mg/dL
• Creatinine no greater than 2.0 mg/dL
• Concurrent corticosteroids for myasthenia gravis or other chronic conditions allowed

You may not qualify if…

• Acute concurrent complications such as infection or post-surgical complications
• Other prior malignancy within the past 5 years unless curatively treated with no evidence of recurrence
• Pregnant or nursing. A negative pregnancy test was required, and fertile patients must use effective contraception
• Prior chemotherapy for metastatic disease. Prior preoperative or adjuvant chemotherapy allowed if disease-free survival prior to recurrence was more than 1 year

Where it is running

• Joliet Oncology-Hematology Associates, Limited - West — Joliet, Illinois, United States
• Swedish-American Regional Cancer Center — Rockford, Illinois, United States
• Carle Cancer Center at Carle Foundation Hospital — Urbana, Illinois, United States
• CCOP - Carle Cancer Center — Urbana, Illinois, United States
• Saint Anthony Memorial Health Centers — Michigan City, Indiana, United States
• Cedar Rapids Oncology Associates — Cedar Rapids, Iowa, United States
• Siouxland Hematology-Oncology Associates, LLP — Sioux City, Iowa, United States
• Mercy Medical Center - Sioux City — Sioux City, Iowa, United States
• St. Luke's Regional Medical Center — Sioux City, Iowa, United States
• Green Bay Oncology, Limited - Escanaba — Escanaba, Michigan, United States
• Dickinson County Healthcare System — Iron Mountain, Michigan, United States
• Borgess Medical Center — Kalamazoo, Michigan, United States
• West Michigan Cancer Center — Kalamazoo, Michigan, United States
• Bronson Methodist Hospital — Kalamazoo, Michigan, United States
• Fairview Ridges Hospital — Burnsville, Minnesota, United States
• Mercy and Unity Cancer Center at Mercy Hospital — Coon Rapids, Minnesota, United States
• Fairview Southdale Hospital — Edina, Minnesota, United States
• Mercy and Unity Cancer Center at Unity Hospital — Fridley, Minnesota, United States
• Hutchinson Area Health Care — Hutchinson, Minnesota, United States
• Meeker County Memorial Hospital — Litchfield, Minnesota, United States
• HealthEast Cancer Care at St. John's Hospital — Maplewood, Minnesota, United States
• Minnesota Oncology Hematology, PA - Maplewood — Maplewood, Minnesota, United States
• Virginia Piper Cancer Institute at Abbott - Northwestern Hospital — Minneapolis, Minnesota, United States
• Hennepin County Medical Center - Minneapolis — Minneapolis, Minnesota, United States
• Rush-Copley Cancer Care Center — Aurora, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.